Celon Pharma
| Company type | Spółka Akcyjna |
|---|---|
| Industry | |
| Founded | 2002 |
| Headquarters | |
Area served | Worldwide |
Key people | Maciej Wieczorek (CEO) |
| Revenue |  PLN 217 million (2023)[1] |
Number of employees | 560 (2023) |
| Website | www.celonpharma.pl |
Celon Pharma S.A is a Polish pharmaceutical company headquartered in Kiełpin, in the Łomianki municipality. Celon Pharma S.A. is an integrated pharmaceutical company conducting advanced scientific research and manufacturing modern medicines. It is engaged in research on innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders.[2]
History
[edit]Celon Pharma, founded in 2002, is an integrated pharmaceutical company focused on both developing generic and innovation solutions. [3]
In 2024 Celon Pharma announced breaking results on treating Schizophrenia with its drug CPL 36
Developed drugs
[edit]Portfolio of Celon Pharma S.A. includes:
- Salmex (fluticasoni propionas + salmeterolum)
- Zarixa (rivaroxaban)
- Aromek (letrozol)
- Donepex (donepezil hydrochloridum)
- Ketrel (quetiapine)
- Valzek (Walsartan) [4]
Innovation segment
[edit]The company is involved in the innovation segment, developing advanced treatments for schizophrenia and depression.
Portfolio:
- CPL'36 - PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic. Beneficial for curing schizophrenia. [3]
Ownership
[edit]The company is owned by its CEO, Maciej Wieczorek.
External links
[edit]- Official website (Polish)
References
[edit]- ^ "Financial report for 2023". Retrieved 20 October 2024.
- ^ "Research and development of Celon Pharma". Retrieved 20 October 2024.
- ^ a b "History of Celon Pharma". Retrieved 20 October 2024.
- ^ "Generic products of Celon Pharma". Retrieved 20 October 2024.